Intranasal vaccine platform has potential for more effective vaccines, fewer side effects

The ongoing COVID-19 pandemic is shining a spotlight on vaccine development. As numerous vaccines race through clinical trials, physicians and researchers continue to develop new vaccine technologies to generate the most effective vaccines with the fewest side effects.A new proof-of-concept study by researchers at the University of Chicago and Duke University demonstrates the potential for one such platform, using self-assembling peptide nanofibers tagged with antigens to prime the immune system against a potential invasion.